Asia Pacific Sickle Cell Disease Treatment Market Size & Outlook
Asia Pacific sickle cell disease treatment market, 2018-2030 (US$M)
Related Markets
Asia Pacific sickle cell disease treatment market highlights
- The Asia Pacific sickle cell disease treatment market generated a revenue of USD 635.3 million in 2023.
- The market is expected to grow at a CAGR of 17.6% from 2024 to 2030.
- In terms of segment, blood transfusion was the largest revenue generating treatment in 2023.
- Pharmacotherapy is the most lucrative treatment segment registering the fastest growth during the forecast period.
- Country-wise, China is expected to register the highest CAGR from 2024 to 2030.
Asia Pacific data book summary
| Market revenue in 2023 | USD 635.3 million |
| Market revenue in 2030 | USD 1,974.4 million |
| Growth rate | 17.6% (CAGR from 2023 to 2030) |
| Largest segment | Blood transfusion |
| Fastest growing segment | Pharmacotherapy |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Bone Marrow Transplant, Blood Transfusion, Pharmacotherapy |
| Key market players worldwide | Novartis AG ADR, Bluebird bio Inc, Pfizer Inc, Bristol-Myers Squibb Co, CRISPR Therapeutics AG, GlycoMimetics Inc, Emmaus Life Sciences Inc, Graphite Bio |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 23.0% of the global sickle cell disease treatment market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 1,974.4 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Sickle Cell Disease Treatment Market Scope
Sickle Cell Disease Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific sickle cell disease treatment market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to sickle cell disease treatment market will help companies and investors design strategic landscapes.
Blood transfusion was the largest segment with a revenue share of 46.48% in 2023. Horizon Databook has segmented the Asia Pacific sickle cell disease treatment market based on bone marrow transplant, blood transfusion, pharmacotherapy covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to Asia Pacific sickle cell disease treatment market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific sickle cell disease treatment market databook
-
Our clientele includes a mix of sickle cell disease treatment market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific sickle cell disease treatment market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific sickle cell disease treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific sickle cell disease treatment market size, by country, 2018-2030 (US$M)
Asia Pacific Sickle Cell Disease Treatment Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
